Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA + CD38 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Tianjin First Central Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA + CD38 CAR-T cells are an investigational dual-targeted chimeric antigen receptor (CAR) T-cell therapy designed for the treatment of relapsed or refractory multiple myeloma. This therapy involves the genetic modification of a patient's T cells to express CARs that simultaneously recognize two distinct antigens highly expressed on malignant plasma cells: B-cell maturation antigen (BCMA) and CD38. By targeting two antigens, the therapy aims to increase the precision of tumor cell elimination and mitigate the risk of immune escape through antigen loss, a common mechanism of resistance in single-target CAR-T therapies. Clinical evaluation, including studies at Tianjin First Central Hospital, focuses on assessing the safety, persistence, and anti-tumor activity of these dual-targeted cells in patients who have exhausted standard treatment options.
- Other names
- BCMA/CD38 dual-target CAR-T cellsBCMA-CD38 CAR-TBCMA-CD-38 CAR-TBCMA-CD 38 CAR-Tanti-BCMA and anti-CD38 CAR-T cells
02
Targets
CD38 (Cluster of Differentiation 38)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA + CD38 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA + CD38 CAR-T cells.